Sarepta Therapeutics· @Sarepta · X·· 2026-01-07AI 评分38
AI 导读
Sarepta宣布已向新西兰药品和医疗器械安全局提交了Study SRP-1005-101的CTA。SRP-1005是一款在研小干扰RNA（siRNA）疗法，用于治疗亨廷顿病。了解更多：https://bit.ly/45lKgz5
正文
Sarepta announced the submission of its CTA for Study SRP-1005-101 to the New Zealand Medicines and Medical Devices Safety Authority. SRP-1005 is an investigational small interfering RNA (siRNA) therapeutic for the treatment of Huntington’s Disease. Read more: https://bit.ly/45lKgz5
来源：Sarepta Therapeutics · x.com